FDA's Preliminary Review Finds No Link Between Ozempic, Wegovy and Suicidal Thoughts

Despite the initial findings, the FDA continues to investigate due to the possibility of a small risk.

FDA's preliminary review finds no evidence that drugs like Ozempic and Wegovy cause suicidal thoughts or actions.
Despite the preliminary findings, the FDA cannot definitively rule out that a small risk may exist.
The review follows a recent federally funded study that showed people taking semaglutide, the medication in Ozempic and Wegovy, had a lower risk of suicidal thoughts than those taking other drugs to treat obesity and diabetes.
The FDA is analyzing reports related to more than a dozen drugs approved since 2005 that are known as GLP-1 receptor agonists.
Patients taking the drugs should report any concerns to health care providers, the FDA said.